T he mainstay of treatment of acute decompensated heart failure is diuretic therapy. While there are no data from long-term, randomized clinical trials showing a morbidity or mortality benefit from the use of chronic diuretic therapy, it is clear that diuretics rapidly improve symptoms associated with volume overload (1) . They promote natriuresis and diuresis, consequently improving symptoms, including pulmonary venous congestion and edema. At present, there are no clear benefits of any particular mode of diuretic therapy, and so any effective means of diuresis is appropriate.
Diuretic Agents
Loop Diuretics. Loop diuretics are the most commonly used diuretics in heart failure. This class of medications includes furosemide, bumetanide, torsemide, and ethacrynic acid, among others. All of the listed loop diuretics are sulfonamide derivatives except for ethacrynic acid. Loop diuretics inhibit the Na ϩ -K ϩ -2Cl Ϫ symporter in the thick ascending limb. This portion of the loop of Henle is responsible for as much as 25% of the resorption of filtered sodium. The combination of the large resorptive capacity of the thick ascending limb as well as the inability of the segments of the nephron distal to the ascending limb to reabsorb a large sodium load explains the efficacy of loop diuretics. Furthermore, the thick ascending limb plays a large role in the formation of the hypertonic medullary interstitium. Without this tonicity, the driving force of water out of the collecting duct in the presence of antidiuretic hormone is greatly reduced.
Loop diuretics inhibit the symporter from the luminal side of the nephron. Loop diuretics are highly protein bound, limiting their filtration into the glomerular lumen. The delivery and concentration of loop diuretics depend on active secretion into the lumen of the proximal tubule. Consequently, the ability of loop diuretics to function is dependent on renal plasma flow; decreased renal function slows delivery into the tubular fluid. The elimination of furosemide is dependent on renal excretion (50%) and conjugation to glucuronic acid within the kidney itself (50%). Bumetanide and torsemide are largely metabolized in the liver.
The dose-response curve of loop diuretics is sigmoidal and depends on the concentration of diuretic at the site of action in the loop of Henle (2) . Clinically, this relationship is important in establishing a threshold below which there will be no diuretic action. Similarly, at the upper end of the curve, there is a ceiling dose of diuretic, above which no additional diuretic action will take place.
The absorption of oral loop diuretics is often discussed. It has been reported that the absorption of furosemide is highly variable (10% to 100%) (3) (4) (5) . In contrast, absorption of both bumetanide and torsemide is reliably higher, ranging from 80% to 100% (4 -6). Variability has been assessed between individuals; there are no data on variability within a given individual. Thus, the clinical significance of variability in absorption is questionable, as for any given individual the diuretic dose will need to be adjusted for an appropriate response. While it is commonly reported that edematous states can also affect the absorption of loop diuretics, data suggest that edema makes little difference in the pharmacokinetics of oral torsemide and furosemide (7) . In a study of massively edematous patients, patients were randomized to oral furosemide or torsemide. Pharmacokinetic measures were made with the first dose of medication and subsequently after the patient had been adequately diuresed (decreased body weight and resolved peripheral edema). There was minimal effect of diuresis on maximal concentration or time to maximum concentration of both furosemide and torsemide.
While loop diuretics are typically used interchangeably, there are some differences in function, although their significance is not clear. Furosemide has weak carbonic anhydrase-inhibiting activity, whereas bumetanide and torsemide do not (8) . Torsemide also appears to have aldosterone antagonistic effects in the rat kidney (9) , although whether this may contribute to outcomes remains to be seen. Two recent open-label studies favored torsemide over furosemide, but these findings need to be verified in a blinded study (10, 11) .
Loop Diuretic Ototoxicity. A common concern with the use of high-dose loop diuretics is ototoxicity. The levels at which furosemide becomes ototoxic are not well established; some authors report a serum concentration of Ͼ50 g/mL as being ototoxic (12) , while others report a concentration of Ͼ100 g/mL in the face of receiving ototoxic agents (i.e., aminoglycosides) as being ototoxic (13) . Rupp (14) measured plasma concentrations of furosemide in patients with renal failure and reported that an infusion rate of 4 mg/min (for intravenous boluses) would not cause levels Ͼ40 g/mL. No patients in that study reported hearing loss. Some studies, however, reported transitory hearing loss with infusion rates of 15-25 mg/min (15, 16) , and these authors recommended that infusion rates not exceed 4 -6 mg/min. Similar data with other loop diuretics are lacking.
These results, while valid for relatively short infusions, do not address longer term continuous loop diuretic infusion. Dormans and colleagues (19) , in studies of continuous furosemide infusion, reported one patient with a creatinine clearance of 14 mL/min/m 2 who, upon receiving 83 mg/hr (total 24-hr dose 2000 mg), had a serum level of 119 g/mL and had transient hearing loss. In the bolus group of this study (doses ranging from 250 to 2000 mg, mean dose 690 mg), seven patients had plasma concentrations of furosemide Ͼ100 g/mL. Five patients had ototoxicity, although the authors did not explicitly specify that the patients with ototoxicity were from this group of seven patients. In contrast, van Meyel et al. (20) claimed that in patients with a creatinine clearance rate Ͼ20 mL/min/ m 2 , an infusion rate of up to 160 mg/hr (a dose generally accepted to be excessive) was safe. Plasma levels ranged from 26.6 to 134.6 g/mL (mean 71.1 g/mL), and only one patient had a level Ͼ100 g/mL. That patient did not have any auditory symptoms. While the data show much variability, the studies suggest that ototoxicity appears to be of concern only with extremely high doses.
Thiazides. Thiazide and thiazide-like diuretics work at the distal convoluted tubules by inhibiting the luminal Na ϩ -Cl Ϫ symporter. The efficacy of diuretics acting at the distal convoluted tubule is limited, however, as only 10% of the filtered load of Na ϩ reaches the distal convoluted tubule; 90% of the filtered load is reabsorbed before reaching it. As with the Na ϩ -K ϩ -2Cl Ϫ symporter, the Na ϩ -Cl Ϫ symporter is found on the luminal side of the tubule. Thiazide diuretics are therefore not effective at glomerular filtration rates Ͻ30 mL/min. Thiazide diuretics increase excretion of K ϩ by the same mechanism as loop diuretics. However, they do so to a greater degree than loop diuretics for a comparable amount of diuresis (21) .
Aldosterone Antagonists. Aldosterone antagonists, such as spironolactone and eplerenone, block the mineralocorticoid receptor (8) . The late distal tubule and collecting duct cells have cytosolic mineralocorticoid receptors with a high affinity for aldosterone. The aldosteronereceptor complexes increase the synthesis of multiple proteins, including aldosterone-induced proteins. It is proposed that among the effects of these proteins is the activation of Na ϩ channels along the luminal membrane and an increase in the activity of the Na ϩ -K Ϫ pump along the basolateral membrane. While the details remain to be elucidated, the net effect of aldosterone is to promote absorption of Na ϩ from the tubular lumen and secretion of H ϩ and K ϩ into the tubular lumen. Aldosterone antagonists bind the mineralocorticoid receptors but subsequently prevent the production of aldosterone-induced proteins. Consequently, sodium retention and potassium excretion are reduced. The resultant retention of potassium can produce clinically important hyperkalemia (22, 23) . Low doses of spironolactone (e.g., 25-50 mg) were shown to reduce morbidity and mortality in patients with New York Heart Association class III-IV heart failure in the RALES trial (24) . There does not appear to be significant diuretic effect at these low doses; rather, it is thought that the benefit in heart failure is due to antagonism of direct myocardial effects of aldosterone.
Choice of Drug (Table 1) . Loop diuretics are the most commonly used class of diuretics for the management of volume overload in heart failure. While there are no data to show improvement in mortality, diuretics have been shown to provide symptomatic relief and improve symptoms (1, (25) (26) (27) (28) (29) (30) (31) . Initial treatment of a patient requiring diuresis can be with a loop diuretic at a dose higher than the patient's chronic dose. While the reflex in the acute setting is to give this initial dose intravenously, there is no clear evidence that intravenous dosing is superior to an oral dose in patients not requiring immediate diuresis. The benefit to intravenous dosing is rapidity in onset of action. In patients on chronic loop diuretics, a dose equivalent to double their chronic dose is a reasonable initial dose. In loop diuretic naïve patients, a reasonable starting dose would be furosemide 20 -40 mg intravenously or 40 -80 mg orally. Alternatively, an intravenous or oral dose of bumetanide 0.5-1 mg or torsemide 5-10 mg can be used. Patients with compromised renal function and heart failure will require higher doses, and doses higher than previously published ceiling doses may be necessary (32) . In these patients, the asymptotic portion of the loop diuretic dose-response curve may be much higher than what is conventionally perceived. Patients should be routinely assessed for adequate response, and if an adequate diuretic response is not seen within 2-3 hrs for an intravenous dose or 4 -6 hrs for a oral dose, additional diuretic should be given at a higher dose.
This strategy will be effective in most patients, but some patients may initially diurese effectively yet not reach a clinically therapeutic end point. While this can often be combated by a simple increase in the diuretic dose, occasionally patients may become resistant to even increasing doses of diuretics.
Diuretic Braking/Diuretic Resistance
The response to administration of a diuretic is a period of diuresis and natriuresis. Following this period, after the diuretic is no longer in the therapeutic range, the body's natural response is to then retain sodium to maintain a net neutral sodium balance (33, 34) . Indeed, in patients given a high-sodium diet (270 mmol/day), net sodium balance over a 24-hr period remained neutral (34) . This naturally occurring response has been termed by some authors postdiuretic sodium retention. Similarly, it has been shown that replacing sodium loses during a period of natriuresis abolishes this increased sodium retention (33) .
Another phenomenon that has been described is that of decreased effectiveness of a diuretic following the initial dose. This phenomenon has been termed diuretic braking and is related to postdiuretic sodium retention in that it is a natural response by the body to maintain sodium and volume homeostasis. In patients fed a high-salt diet, there was no difference in sodium excretion between the first and third doses of bolus furosemide; in patients on a low-sodium diet, however, there was a marked decrease in urinary sodium excretion. Importantly, however, despite this decrease in urinary sodium excretion, it was only in the lowsalt diet group that a negative sodium balance was maintained over the duration of the study; the high-salt diet group was able to replace all diuretic-induced sodium losses during the period of postdiuretic sodium retention (34) . While it is clear that this decrease in response to diuretic is mediated by sodium loss and the body's attempt to maintain sodium homeostasis, it is thought that there is a volume component as well. Physiologically, this is a reasonable theory. Experimental models, however, are confounded in that adequate volume replacement is given with sodium (33, 35, 36) .
Over the longer term, delivery of highsodium loads to the distal convoluted tubule can result in adaptation and increased resorption. There is increased ability to transport Na ϩ from the tubule lumen in animal models of chronic highsodium loads (5, (37) (38) (39) . The increase in Na transport in these cells has also been demonstrated in humans (40). Loon et al. (40) measured baseline increases in sodium excretion in patients who had not recently been on diuretics. Patients were treated with placebo, furosemide (40 mg twice daily), or chlorothiazide (500 mg twice daily) for 1 month in a crossover fashion. Following 1 month of treatment, patients were given furosemide (10 mg intravenous bolus, followed by 15 mg/hr for 3 hrs). In addition, a bolus of chlorothiazide (500 mg intravenously) was given after 150 mins of furosemide infusion. The authors found a response to the furosemide infusion in all three groups. However, the increase in the chlorothiazide and furosemide groups was lower than in the placebo group. After the addition of chlorothiazide, the group that had been on furosemide showed a further increase in fractional excretion of sodium.
Other proposed mechanisms for decreased diuretic effectiveness include increased renal nerve activity, activation of the renin-angiotensin-aldosterone pathway, and hypertrophy of distal tubule epithelial cells. Evidence on the role of renal nerves in the control of renal blood flow, glomerular filtration rate, and sodium retention is conflicting. While stimulation of renal nerves by volume depletion results in increased sodium retention mediated by release of renin, renal denervation has not been demonstrated to affect this response (41) (42) (43) (44) . The importance of the renin-angiotensin-aldosterone pathway is clear, however. In animal models, hypertrophy of the distal convoluted tubule and collecting duct has been demonstrated and is thought to contribute to the increased distal sodium handling (37, 38, (45) (46) (47) .
Understanding these mechanisms to decreased diuretic effectiveness gives rise to additional therapeutic options.
Continuous Infusions. There have been many uncontrolled or small reports related to the efficacy of continuous infusions of loop diuretics. Comparison with bolus dosing is difficult, as natriuresis or aquaresis could be increased in either group by increasing the dose used. Thus, while these studies support the efficacy of continuous infusions, they do not prove superiority to appropriate bolus administration.
Some studies of continuous infusions of bumetanide or furosemide have demonstrated higher sodium excretion and urine output compared with boluses at medium to high doses (bumetanide, 12 mg over 12 hrs; furosemide, 180 -3840 mg over 24 hrs) (17) (18) (19) 48) . However, Aaser et al. (49) did not find any difference in urine output or sodium excretion at a lower dose of furosemide (mean 145 mg, range 80 -320 mg). Likewise, Kramer et al. (18) found equivalent sodium excretion and urine output in a comparison of bolus torsemide with continuous infusion (total 24-hr dose, 100 mg). A proposed benefit to continuous infusion of loop diuretics is the prevention of potentially detrimental neurohormonal activation with diuretic administration (50). This does not appear to be the case, however. In a study by Aaser et al. (49) , plasma concentrations of antidiuretic hormone, norepinephrine, epinephrine, and neuropeptide Y were equivalent in patients treated with a 24-hr continuous infusion or with bolus administration of furosemide.
Ferguson et al. (51) compared the effects of two 3.25-mg bumetanide boluses, given 6 hrs apart, with that of a 0.5-mg bumetanide bolus followed by continuous infusion of 0.5 mg of bumetanide per hour for 12 hrs in a randomized crossover study of eight patients with New York Heart Association class II-III heart failure. At 6 hrs, patients in both groups received a 1-hr 0.45% saline infusion totaling the lesser of one half total urinary volume or 1000 mL. This study is revealing in that sodium excretion up to the point of the sodium load was essentially the same (228 Ϯ 77 mEq for the infusion group compared with 206 Ϯ 100 mEq for the bolus group). However, the continuous infusion of bumetanide allowed 86% Ϯ 15% of the sodium load to be excreted compared with only 29% Ϯ 30% with the bolus dosing (p ϭ .0005). This is consistent with what is known about bumetanide pharmacokinetics; the timing of the sodium load was after the peak effect of bumetanide. This supports the theory that a continuous infusion of loop diuretic can combat the postdiuretic sodium retention. Unfortunately, there are no studies on the diuretic and natriuretic course after a chronic diuretic infusion is discontinued.
The need for appropriate dosing and the efficacy of close monitoring and frequent adjustments of either bolus or continuous infusions were demonstrated by Schuller et al. (51a) in a randomized trial of medical intensive care unit patients with pulmonary edema. Patients were randomized to treatment with a contin-uous infusion of furosemide or bolus dosing of furosemide. All patients received a 40-mg intravenous bolus. Patients in the continuous infusion group were then started on a drip at 0.1 mg/kg/hr, which was then titrated to achieve diuresis of 1 mL/kg/hr. The infusion rate was increased hourly by 0.1 mg/kg to a maximal rate of 0.75 mg/kg/hr. The bolus group was reassessed frequently; if the net hourly diuresis was Ͻ1 mL/kg/hr, an additional bolus dose, double the previous dose, was given within 1-2 hrs. If the net hourly diuresis was adequate (Ͼ1 mL/kg/ hr), the previous dose was repeated within 4 -6 hrs. Patients were diuresed to what the authors termed a therapeutic end point. The authors found no differences in the time to reach the therapeutic end point or in the total amount of diuretic used. Both groups had diuresed ‫5.1ف‬ L at 6 hrs, and at 24 hrs, the bolus group had diuresed approximately 4 L and the continuous infusion group ‫5.5ف‬ L (p not significant). The amount of furosemide was similar in both groups, ‫051ف‬ mg administered at 6 hrs, and, at 24 hrs, ‫004ف‬ mg in the bolus group and ‫054ف‬ mg in the continuous infusion group (p not significant).
Continuous-infusion protocols are highly varied. Doses for bumetanide range from 0.5-to 1-mg loading doses and 0.5 to 1 mg/hr (48, 51) . For furosemide, infusion protocols have ranged from 5 to 40 mg/hr, with a loading dose up to 100 mg sometimes given (17-20, 49, 52) . It has been recommended that a loading dose be given in order to reduce the time to therapeutic drug concentrations (3). While titration up to 160 mg/hr has been reported (20) , few people believe that such high infusion rates are safe or appropriate.
It is difficult to draw any conclusions about outcomes based on the small, heterogeneous studies done with infusion vs. bolus diuretics. None of the studies rigorously examined the period following diuretic infusion, and so true comparisons regarding postdiuretic sodium retention are limited. There currently is no evidence that continuous infusion of loop diuretics prevents postdiuretic sodium retention, nor is there any particular reason to think that this would be the case. Several of the studies comparing bolus with continuous infusion (17) (18) (19) discuss "diuretic efficiency" (sodium excretion/ diuretic excretion), although the clinical importance of this measure is unclear. It does appear that the effectiveness of loop diuretics is largely based on dose and sodium intake.
Thus, the first step in treating diuretic resistance is to ensure that Na ϩ intake is minimized (Յ2 g/day) and that the diuretic dose is sufficient. To the extent that a higher dose of diuretic may be given safely with continuous infusion, it may be a better option when extremely large doses are desired. Infusion rates for patients with normal renal function can be on the low end of the infusion range, while patients with renal dysfunction will require higher infusion rates (Table 2) . For patients who are already receiving bolus doses of diuretics, the previous dose can be converted to an hourly rate and then increased. Most important, patients should be reassessed regularly and the infusion rate increased or decreased as appropriate. An additional bolus dose can be given with each increase. There is no optimal dosing regimen; adjustments will need to be made for each individual patient.
Dual Diuretic Therapy. Given the ability of the distal convoluted tubule to increase its sodium resorption capacity, another approach to combating diuretic resistance is the addition of a second diuretic agent, such as a thiazide or thiazide-like diuretic (53) (54) (55) (56) (57) (58) . Hydrochlorothiazide and metolazone, as well as bendrofluazide, have been used, and there is no evidence that one is superior (59) . It has been suggested that the diuretic affecting the distal tubule be given before the loop diuretic in order to fully block the distal convoluted tubule (39, 60) . Metolazone, however, may have a half-life of as long as 2 days, making this inconvenient dosing regimen unnecessary. For other thiazide diuretics, no benefit of staggered dosing has been demonstrated. This dosing is also clearly not needed when oral loop diuretics are used.
High doses of thiazide/thiazide-like diuretics (metolazone 10 mg, hydrochlorothiazide 50 -100 mg) have been recommended previously. Since these doses have been associated with reports of excessive electrolyte and fluid depletion (53) , it is advisable to start a lower dose (hydrochlorothiazide 12.5-25 mg or metolazone 2.5-5 mg) when possible. Regardless of the dose chosen, patients' electrolytes should be closely monitored during dual diuretic therapy.
While the effectiveness of a thiazide diuretic in combination with a loop diuretic is well described, the diuretic effect of low-dose aldosterone antagonism has been studied less. High doses of spironolactone (100 -200 mg daily) are frequently used in ascites and volume overload related to liver cirrhosis. The addition of 100 mg of spironolactone to patients with poor response to bumetanide results in increased natriuresis and diuresis (61, 62) . In those patients not prone to hyperkalemia, spironolactone at doses higher than the 25-50 mg used in the RALES trial may be an alternative.
CONCLUSIONS
Administration of loop diuretics in low to moderate doses, given either orally or as intravenous boluses, remains the cornerstone of treating the congestive symptoms in heart failure. The dose of diuretic must be in the therapeutic range (above the threshold). Patients exhibiting decreased responsiveness to diuretics can be treated with higher doses, continuous infusions, or the addition of a thiazide diuretic or aldosterone antagonist. 
